Cagrilintide Side Effects: What 450 Users Actually Report (2026)

Most cagrilintide side effects are gastrointestinal and mild-to-moderate — a decreased appetite (the intended effect) and nausea lead the list, followed by constipation, vomiting, and diarrhea — and they tend to ease as the body adjusts; the single most important twist is that this picture gets noticeably stronger when cagrilintide is combined with semaglutide as CagriSema, the form most trials actually study. Cagrilintide sits among the peptides people use for weight loss, so tolerability is a core part of choosing it. This page answers the real tolerability question two ways at once: what 450 ProtocolPlus users report from real use, placed honestly next to the still-emerging trial record — because cagrilintide is investigational, with no approved label and no validated long-term incidence yet.

Most "cagrilintide side effects" pages recycle one trial's adverse-event list. We do it differently. The headline below is first-party community data — what 450 ProtocolPlus users who tracked cagrilintide tolerability actually report — kept honestly beside the cagrilintide and CagriSema trial record as the only validated benchmark that exists. For the molecule itself (the amylin mechanism, the weight-loss results, its legal status), this page links up to the cagrilintide complete guide so it stays a clean safety-and-tolerability hub.

Key Takeaways

• The honest top line (what our users report, N=450): the most common effects are the intended decreased appetite (40%, 180 users) and nausea (38%, 171), followed by constipation (20%, 90), vomiting (18%, 81), and diarrhea (16%, 72). These are mostly mild-to-moderate and gastrointestinal, and they cluster around dose increases.
• It's GI-dominant for a reason. Cagrilintide is a long-acting amylin analog: amylin slows gastric emptying and signals fullness in the hindbrain, so the body's first responses are digestive — reduced hunger, nausea, and altered bowel habits.
• The combination amplifies it. Cagrilintide is most often studied with semaglutide as CagriSema, and the combined GI burden is higher than either drug alone — in the Phase-3 REDEFINE 1 trial, GI adverse events hit roughly 80% of the CagriSema group, with nausea around 55%, versus a lower rate for cagrilintide on its own.
• Investigational means the picture is incomplete. There is no FDA-approved label and no validated long-term incidence for cagrilintide. Novo Nordisk filed CagriSema with the FDA in December 2025, but as of now everything known comes from clinical trials — so read our community figures as early self-report, not established risk.
• The one serious effect to watch: severe hypoglycemia (0.5%, 2 users) — rare, and mostly a concern if cagrilintide is combined with insulin or a sulfonylurea. Self-report ≠ trial incidence ≠ causation, and absence of widely reported harm is not proof of safety.

What are the most common cagrilintide side effects?

Across 450 ProtocolPlus users who tracked cagrilintide tolerability, the most-reported effects are the intended decreased appetite (40%) and nausea (38%), followed by constipation (20%), vomiting (18%), and diarrhea (16%) — almost all mild-to-moderate, gastrointestinal, and worst right after a dose increase. This is a community-report ranking from our own app data, not a validated incidence table, and because cagrilintide is investigational there is no approved label to compare it against.

The pattern is exactly what cagrilintide's mechanism predicts. As a long-acting amylin analog, it slows how fast the stomach empties and signals satiety in the brainstem, so reduced hunger and digestive complaints dominate the list. After the top GI cluster, reports tail off into milder, less specific effects: abdominal pain (12%, 54 users), fatigue (12%, 54), injection-site reactions (10%, 45), dyspepsia or indigestion (10%, 45), headache (8%, 36), and dizziness (5%, 22). The rare-but-serious tail is a single effect — severe hypoglycemia (0.5%, 2) — covered in its own red-flag block below.

These shares come only from our community-reported dataset and describe what people experience and log, not trial-grade incidence and not causation. The receptor-level mechanism lives on the hub; for the molecule itself see the cagrilintide complete guide.

Citation capsule. Among 450 ProtocolPlus users who tracked cagrilintide tolerability, the most-reported effects were decreased appetite (40%, 180 users, largely the intended effect), nausea (38%, 171), constipation (20%, 90), vomiting (18%, 81), and diarrhea (16%, 72). This is first-party data reflecting what the community reports — self-reported, not validated trial incidence, and not proof of causation. Source: ProtocolPlus app data (side-effects/cagrilintide.json), 2026.

When should you seek urgent care on cagrilintide?

Seek urgent care for signs of severe low blood sugar — confusion, shaking, sweating, blurred vision, or fainting — and treat persistent vomiting or diarrhea that stops you holding down fluids as a dehydration risk that needs medical attention rather than something to push through. Severe hypoglycemia is the one effect in our data tagged "severe," and it is rare (0.5%, 2 of 450 reporters) — but because cagrilintide is investigational, the long-term risk picture is genuinely incomplete, which is a reason to take any red flag more seriously and involve a clinician early.

These are not the everyday nausea-and-titration effects. They are the small-but-serious end of the distribution, each with a clear warning sign and a clear action. Cagrilintide on its own caused no clinically significant hypoglycemia in its trials — the concern rises mainly when it is stacked with insulin or a sulfonylurea — so the red flags below reflect rare community self-reports plus the precautionary cautions that follow from the drug's GI-dominant, gastric-slowing profile.

Citation capsule. In the cagrilintide dose-finding Phase 2 trial (Lau et al., Lancet 2021), gastrointestinal events were the most common adverse events and were dose-dependent, while no clinically significant hypoglycemia was reported on cagrilintide monotherapy; serious adverse events occurred in roughly 2–7% across dose groups. Cagrilintide remains investigational with no FDA-approved label and no boxed warning. Source: The Lancet (Lau et al.), 2021.

What do the common cagrilintide side effects feel like, and how do people manage them?

The common effects are gastrointestinal, mostly mild-to-moderate, tend to peak in the days after a dose increase, and ease over the following weeks as the body adapts — which is exactly why cagrilintide is titrated up slowly in trials. Below is each frequent effect: what it feels like, why it happens, when it tends to start and ease, and how our community manages it. These are descriptions of community practice, not a prescription — and for an investigational drug there is no approved dosing to optimize against, so dose decisions belong entirely with a clinician (the molecule and its trial dosing are on the cagrilintide complete guide).

Decreased appetite (40%, 180 users)

The single most reported effect, and worth a special note: for most users this is the intended effect, not an adverse one — reduced appetite is how cagrilintide produces weight loss, by amplifying the body's natural "I'm full" signal. We track it because it occasionally becomes excessive, with people skipping meals entirely or under-eating to the point of fatigue, dizziness, or dehydration. The community workaround is protein-forward meals on a schedule (eating by the clock rather than by hunger) so intake stays adequate even when appetite is low.

Nausea (38%, 171 users)

The most common true side effect, and usually the one people worry about most before starting. It comes directly from cagrilintide's mechanism: amylin slows gastric emptying, so food sits in the stomach longer and the stomach feels full and queasy. In trials nausea was clearly dose-dependent and clustered in the dose-escalation weeks, typically worst in the first day or two after a dose step-up before fading over the following one to two weeks. Community practice leans on smaller, more frequent meals, stopping at the first sign of fullness, avoiding greasy or very large meals, staying hydrated, and not rushing the next dose increase.

Constipation and diarrhea (20% and 16%)

Cagrilintide can push gut motility in either direction, but with a slow-emptying amylin drug constipation tends to be the more prominent of the two. Constipation (90 users) is usually a slow build tied to eating and drinking less and to slower transit; diarrhea (72 users) is more often transient around dose changes. Community practice is straightforward: fluids and fiber for constipation, bland low-residue foods and electrolytes for diarrhea, and watching for dehydration when either is severe or persistent.

Vomiting (18%, 81 users)

Less common than nausea and usually linked to a too-fast titration or a large, greasy meal. The reason it earns a "moderate" tag is that persistent vomiting risks dehydration and, in turn, kidney strain. Occasional vomiting is generally managed like nausea; vomiting that keeps you from holding down fluids is a reason to call a clinician, not to push through.

The milder tail (abdominal pain, fatigue, injection-site, dyspepsia, headache, dizziness)

Abdominal pain (12%) is usually mild and gas-related — but remember the red flag: severe, persistent, radiating pain is the precautionary pancreatitis signal, not ordinary cramping. Fatigue (12%), headache (8%), and dizziness (5%) often track with eating and drinking less early on and tend to settle. Dyspepsia or indigestion (10%) is a natural consequence of slower gastric emptying. Injection-site reactions (10%) — redness, itching, or a small lump — are typically minor and tied to weekly subcutaneous dosing.

How the CagriSema combination changes the picture

This is the part most cagrilintide pages gloss over. Cagrilintide is most often used and studied with semaglutide as CagriSema, and stacking two appetite-and-gut-acting drugs adds their gastrointestinal burdens together — so the combination reliably reports more GI effects than cagrilintide alone. In the Phase-3 REDEFINE 1 obesity trial, gastrointestinal adverse events occurred in roughly 80% of the CagriSema group (versus about 40% on placebo), with nausea around 55%, vomiting about 26%, and constipation about 31% — higher than the rates seen for cagrilintide monotherapy (where GI events ran roughly 41–63% depending on dose) and shifted upward from semaglutide alone. The reassuring counterweight is that most of these events were mild-to-moderate and transient, and treatment discontinuation stayed low (about 6% in REDEFINE 1) — most people who feel queasy ride it out rather than quit. If you are taking, or considering, the combination rather than cagrilintide on its own, plan for the stronger GI version of this profile, and read our community figures (cagrilintide-focused) as the floor, not the ceiling.

When do the side effects start and ease? (the time-course)

The reason "go slow" works is that the side-effect curve is tied to the dose-escalation schedule, not a fixed calendar date. In the trials cagrilintide is started low (around 0.25 mg) and stepped up over several weeks specifically to keep the GI effects tolerable, on the way to the 2.4 mg target dose. The pattern most people describe is a small flare in the first day or two after each dose increase, then a settle over the next one to two weeks as the body adapts — followed by a fresh, usually milder flare at the next step-up. By the time someone reaches and holds their dose, the day-to-day GI complaints have typically faded for most users, which is why tolerability reports are heaviest during titration and lighter afterward. With CagriSema, both halves are titrated together, which is why the combination is escalated especially cautiously.

Our take: The single biggest lever on tolerability is titration speed. Almost every common effect on this page is dose-step-related and eases with time, so the community pattern that works is "go slow, hold a dose longer if you need to, and don't chase the next increase." This matters double for the CagriSema combination, where two GI-acting drugs add up. Comfort beats speed — especially for a compound whose long-term safety is still being studied.

How does our community report compare to the cagrilintide trial record?

Our community-reported pattern lines up with the direction of the trials — GI effects lead, nausea and the intended appetite drop dominate — but the comparison is looser than for an approved drug, because cagrilintide has no FDA label and only a thin, still-emerging trial record to check against, most of it from the CagriSema combination rather than cagrilintide alone. The honesty framing matters more here than for any approved compound: community self-report, controlled-trial incidence, and (eventually) real-world rates are three different things, and for an investigational drug the validated middle column is mostly still being written.

Two honesty points sit on top of the comparison. First, decreased appetite is largely the intended effect — it appears in the trials too, but counting it as a "side effect" overstates the harm side of the ledger, so we flag it rather than rank it as adverse. Second, and most important for cagrilintide: most published adverse-event data is for the combination (CagriSema), not the molecule alone. Our community figures center on cagrilintide tolerability, so they sit below the headline CagriSema GI rates — and that gap is the point, not an error. Someone on cagrilintide monotherapy and someone on CagriSema are looking at two different intensities of the same GI-dominant profile.

There is also a clear dose-dependence story. In the cagrilintide Phase-2 dose-finding trial, GI adverse events climbed with dose — from the low-40s percent at the bottom of the range to the low-60s at the top 4.5 mg dose, with nausea scaling the same way. So a conservative starting dose and a pushed top dose are, in effect, two different side-effect profiles of the same molecule, which is why a single community average is best read alongside the dose and whether semaglutide is on board.

The table below places our community report next to what the cagrilintide and CagriSema trials describe, for the effects where a comparison is meaningful. Because no approved label exists, the trial column is directional, not a validated incidence table.

Why does cagrilintide cause these side effects?

Almost every common cagrilintide side effect traces back to one mechanism: it is a long-acting amylin analog, and amylin slows how fast the stomach empties while signaling fullness in the hindbrain — so the body's first responses are digestive (nausea, fullness, altered bowel habits) and a reduced appetite. That single cause is also why the effects are dose-related and why slow titration tames them. The deep receptor science lives on the hub; this is the short version that explains the pattern above.

The mechanism maps cleanly onto the symptom list. Slowed gastric emptying is the direct driver of nausea, early fullness, dyspepsia, and the tendency toward constipation — food and gut contents simply move more slowly. The satiety signal that cagrilintide amplifies through amylin receptors (the calcitonin-receptor/RAMP complexes in the brainstem's appetite centers) is what produces the intended decreased appetite. The serious concerns are framed cautiously by design: hypoglycemia is mainly a worry when cagrilintide is stacked with insulin or a sulfonylurea (the trials in non-diabetic participants saw no clinically significant hypoglycemia on cagrilintide alone), and pancreatitis is a precautionary class-level flag rather than a confirmed cagrilintide-specific finding. And because cagrilintide is most often used with semaglutide — a GLP-1 drug that also slows gastric emptying and curbs appetite — the two mechanisms overlap and reinforce each other, which is the mechanistic reason the CagriSema combination's GI burden is higher than either drug alone. For the full receptor-level science and the weight-loss results, see the cagrilintide complete guide.

Citation capsule. Cagrilintide is a long-acting amylin analog that activates amylin receptors (AMY1R/AMY3R) in the hindbrain to increase satiety and slow gastric emptying, which accounts for its dose-related, GI-dominant side-effect profile; hypoglycemia risk rises mainly with concomitant insulin or sulfonylureas. Because it is most often combined with the GLP-1 drug semaglutide as CagriSema — which also slows gastric emptying — the combination's gastrointestinal burden is higher than either agent alone. Source: The Lancet (Lau et al.; Enebo et al.), 2021; NEJM REDEFINE 1, 2025.

Who should be cautious, and who should avoid cagrilintide?

Because cagrilintide is investigational and unapproved, the honest baseline is that no one has an established safe-use profile yet — but the trial-informed cautions point most clearly at people on insulin or a sulfonylurea (hypoglycemia risk), people with a history of pancreatitis or significant GI disease (including gastroparesis or other gastric-motility problems, which a gastric-slowing drug can worsen), those prone to dehydration, and pregnancy (not studied, avoid). These are the practical lines that follow from the side-effect profile; everything else is a conversation with a clinician about your specific history.

A few cautions follow directly from the data above. Because cagrilintide slows gastric emptying, anyone with pre-existing slow stomach emptying or severe GI disease should approach it carefully, and persistent vomiting or diarrhea deserves extra attention in older adults and anyone with kidney concerns, since dehydration is the usual path to kidney strain. Anyone combining cagrilintide with other glucose-lowering medication needs those doses reviewed to avoid hypoglycemia — a caution that grows when it is taken as CagriSema, where the combined GI load is heavier. And because cagrilintide is only available as a research-grade ("for research use only") compound ahead of approval, those versions are unregulated for human use and add quality and dosing uncertainty on top of the drug's own emerging profile; for how to think about that, see how to vet peptide quality. None of this page replaces a clinician conversation — and with an investigational drug, that conversation matters more, not less. If you are weighing cagrilintide against the approved incretin options, our semaglutide side effects and retatrutide side effects pages compare the tolerability profiles.

Frequently Asked Questions

The bottom line

If you came here worried about cagrilintide side effects, the honest answer has an extra layer because cagrilintide is still investigational and rarely used by itself. The effects you will most likely feel are gastrointestinal and mild-to-moderate — the intended drop in appetite leads, nausea close behind, then constipation, vomiting, and diarrhea — and they mostly ease with slow titration and a few practical habits. What sets cagrilintide apart is why the profile is so GI-heavy: as an amylin analog it slows gastric emptying, so digestion-related symptoms dominate.

The twist you actually need to plan for is the CagriSema combination: because cagrilintide is most often paired with semaglutide, and both drugs slow the gut and curb appetite, the combined GI burden runs higher than cagrilintide alone — roughly 80% any-GI and ~55% nausea in the Phase-3 trial. The one effect to watch is the rare severe hypoglycemia (0.5% of our reporters), mainly a concern alongside insulin or a sulfonylurea, and the line that ends self-management is severe, persistent abdominal pain or vomiting you cannot keep ahead of. And keep the biggest caveat in view: there is no approved label and no validated long-term incidence here yet, so every number on this page — ours included — is early. From here, the natural next reads are the cagrilintide complete guide for the molecule and trial results, and our semaglutide side effects and retatrutide side effects pages if you are comparing the options.

Sources

• Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial." The Lancet, 2021;398(10317):2160–2172. (Dose-dependent GI adverse events 41–63%; nausea 20–47%; no clinically significant hypoglycemia on monotherapy; serious AEs ~2–7%.) Retrieved 2026-06-18. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01751-7/abstract
• Enebo LB, Berthelsen KK, Kankam M, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial." The Lancet, 2021;397(10286):1736–1748. (Combination tolerability; nausea most common AE; clusters in dose-escalation weeks; ~4% AE discontinuation.) Retrieved 2026-06-18. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/abstract
• Garvey WT, Blüher M, Contreras C, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)." New England Journal of Medicine, 2025. DOI 10.1056/NEJMoa2502081. (CagriSema GI adverse events ~79.6% vs 39.9% placebo; nausea ~55%; vomiting ~26%; constipation ~31%; discontinuation ~6%; 22.7% weight reduction.) Retrieved 2026-06-18. https://www.prnewswire.com/news-releases/cagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html
• Novo Nordisk. "Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management." Press release, 2025-12-18. (Investigational status; U.S. FDA filing; review expected 2026.) Retrieved 2026-06-18. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
• Becerril S, Frühbeck G. "Cagrilintide: a long-acting amylin analogue for the treatment of obesity." eBioMedicine (Lancet Discovery Science), 2025. (Amylin pharmacology: AMY1R/AMY3R hindbrain satiety signaling; slowed gastric emptying.) Retrieved 2026-06-18. https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/
• ProtocolPlus. "Community-reported tolerability data: cagrilintide" (side-effects/cagrilintide.json). First-party app data, 2026. N = 450 users who tracked cagrilintide tolerability. Self-reported community frequency for an investigational compound — not validated incidence and not proof of causation.